Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 6/2011

Open Access 01-12-2011 | Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Beyond Genome-Wide Association Studies: New Strategies for Identifying Genetic Determinants of Hypertension

Authors: Xiaoling Wang, Bram P. Prins, Siim Sõber, Maris Laan, Harold Snieder

Published in: Current Hypertension Reports | Issue 6/2011

Login to get access

Abstract

Genetic linkage and association methods have long been the most important tools for gene identification in humans. These approaches can either be hypothesis-based (i.e., candidate-gene studies) or hypothesis-free (i.e., genome-wide studies). The first part of this review offers an overview of the latest successes in gene finding for blood pressure (BP) and essential hypertension using these DNA sequence–based discovery techniques. We further emphasize the importance of post–genome-wide association study (post-GWAS) analysis, which aims to prioritize genetic variants for functional follow-up. Whole-genome next-generation sequencing will eventually be necessary to provide a more comprehensive picture of all DNA variants affecting BP and hypertension. The second part of this review discusses promising novel approaches that move beyond the DNA sequence and aim to discover BP genes that are differentially regulated by epigenetic mechanisms, including microRNAs, histone modification, and methylation.
Literature
1.
Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516–7.PubMedCrossRef
2.
Nolte IM, McCaffery JM, Snieder H. Candidate gene and genome-wide association studies in behavioral medicine. In: Steptoe A, editor. Handbook of behavioral medicine: Methods and applications. New York: Springer; 2010. p. 423–41.CrossRef
3.
Ott J, Kamatani Y, Lathrop M. Family-based designs for genome-wide association studies. Nat Rev Genet. 2011;12(7):465–74.PubMedCrossRef
4.
Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–61.PubMedCrossRef
5.
6.
7.
Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep. 2010;12(1):17–25.PubMedCrossRef
8.
Zhang K, Weder AB, Eskin E, O’Connor DT. Genome-wide case/control studies in hypertension: only the ‘tip of the iceberg’. J Hypertens. 2010;28(6):1115–23.PubMed
9.
Wang X, Snieder H. Genome-wide association studies and beyond: what’s next in blood pressure genetics? Hypertension. 2010;56(6):1035–7.PubMedCrossRef
10.
Cowley Jr AW. The genetic dissection of essential hypertension. Nat Rev Genet. 2006;7(11):829–40.PubMedCrossRef
11.
12.
• Newton-Cheh C, Larson MG, Vasan RS, et al.: Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009, 41(3):348–353. This large-scale candidate gene study showed that SNPs in the genes that code for atrial and B-type natriuretic peptides also show association with systolic and diastolic BP.
13.
Sõber S, Org E, Kepp K, et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One. 2009;4(6):e6034.PubMedCrossRef
14.
Tomaszewski M, Debiec R, Braund PS, et al. Genetic architecture of ambulatory blood pressure in the general population: insights from cardiovascular gene-centric array. Hypertension. 2010;56(6):1069–76.PubMedCrossRef
15.
•• Levy D, Ehret GB, Rice K, et al.: Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41(6):677–687. This paper and the one by Newton-Cheh et al. [16••] were the first successful GWAS meta-analyses for blood pressure, identifying 13 independent BP loci.
16.
•• Newton-Cheh C, Johnson T, Gateva V, et al.: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41(6):666–676. This paper and the one by Levy et al. [15••] were the first successful GWAS meta-analyses for blood pressure, identifying 13 independent BP loci.
17.
• Johnson AD, Newton-Cheh C, Chasman DI, et al.: Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. Hypertension 2011, 57(5):903–910. This study shows that candidate gene studies for BP and hypertension may be successful if using meta-GWAS-type sample sizes.
18.
Rao F, Wen G, Gayen JR, et al. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352–372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation. 2007;115(17):2271–81.PubMedCrossRef
19.
• Ji W, Foo JN, O’Roak BJ, et al.: Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40(5):592–599. This landmark study proved that rare variants may have a considerable effect on BP in the general population.
20.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545–56.PubMedCrossRef
21.
22.
Carrs KJ, Stowasser M, Gordon RD, O’Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens. 2011;25(9):560–4.CrossRef
23.
Takeuchi F, Isono M, Katsuya T, et al. Blood pressure and hypertension are associated with 7 loci in the Japanese population. Circulation. 2010;121(21):2302–9.PubMedCrossRef
24.
Ho JE, Levy D, Rose L, et al. Discovery and replication of novel blood pressure genetic loci in the Women’s Genome Health Study. J Hypertens. 2010;29(1):62–9.CrossRef
25.
• Padmanabhan S, Melander O, Johnson T, et al.: Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010, 6(10):e1001177. This first successful GWAS for hypertension used an extreme case-control design and identified a locus near the Uromodulin gene.
26.
Adeyemo A, Gerry N, Chen G, et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 2009;5(7):e1000564.PubMedCrossRef
27.
Fox ER, Young JH, Li Y, et al. Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet. 2011;20(11):2273–84.PubMedCrossRef
28.
• Zhu X, Young JH, Fox E, et al.: Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet 2011, 20(11):2285–2295. This paper shows that admixture mapping combined with large-scale follow-up association analysis may be a more powerful alternative than GWAS in admixed populations such as African Americans.
29.
•• Kato N, Takeuchi F, Tabara Y, et al.: Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011, 43(6):531–538. This study shows that the meta-GWAS formula can be successfully transferred to other ethnic groups. In large sample sizes of east Asians, seven European BP loci were confirmed and six novel loci identified.
30.
•• Freedman ML, Monteiro AN, Gayther SA, et al.: Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011, 43(6):513–518. This is the first study to highlight the importance of post-GWAS analysis and comprehensively describe its principles.
31.
Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models and data. Am J Hum Genet. 2001;69(1):1–14.PubMedCrossRef
32.
• The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010, 467(7319):1061–1073. This paper describes the aims of the 1000 Genomes Project and provides the results of its pilot phase.
33.
Medvedev P, Stanciu M, Brudno M. Computational methods for discovering structural variation with next-generation sequencing. Nat Methods. 2009;6(11 Suppl):S13–20.PubMedCrossRef
34.
Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.PubMed
35.
Ge D, Zhang K, Need AC, et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res. 2008;18(4):640–3.PubMedCrossRef
36.
Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362–7.PubMedCrossRef
37.
Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.PubMedCrossRef
38.
Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4.PubMedCrossRef
39.
Conde L, Vaquerizas JM, Dopazo H, et al.: PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res 2006, 34(Web Server issue):W621-625.
40.
Annilo T, Kepp K, Laan M. Natural antisense transcript of natriuretic peptide precursor A (NPPA): structural organization and modulation of NPPA expression. BMC Mol Biol. 2009;10:81.PubMedCrossRef
41.
Quigley D, Balmain A. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet. 2009;10(9):651–7.PubMedCrossRef
42.
Szklarczyk D, Franceschini A, Kuhn M, et al.: The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 2011, 39(Database issue):D561-568.
43.
Kanehisa M, Goto S, Furumichi M, et al.: KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010, 38(Database issue):D355-360.
44.
Snieder H, Harshfield GA, Dekkers JC, Treiber FA. Heritability of resting hemodynamics in African and European American youth. Hypertension. 2003;41:1196–201.PubMedCrossRef
45.
Wang X, Snieder H. Familial aggregation of blood pressure. In: Flynn JT, Ingelfinger JR, Portman RJ, editors. Clinical hypertension and vascular diseases: pediatric hypertension. 2nd ed. Totowa: Humana Press Inc; 2011. p. 241–58.
46.
Feng T, Zhu X. Genome-wide searching of rare genetic variants in WTCCC data. Hum Genet. 2010;128(3):269–80.PubMedCrossRef
47.
Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature. 2010;464(7289):713–20.PubMedCrossRef
48.
Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6.PubMedCrossRef
49.
Putku M, Kepp K, Org E, et al. Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans. Hum Mutat. 2011;32(7):806–14.PubMedCrossRef
50.
51.
Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–40.PubMedCrossRef
52.
Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39(Database issue):D152-157.
53.
Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010;20(5):589–99.PubMedCrossRef
54.
Ohtani K, Dimmeler S. Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol. 2011;106(1):5–11.PubMedCrossRef
55.
Zhang C. MicroRNAs in vascular biology and vascular disease. J Cardiovasc Transl Res. 2010;3(3):235–40.PubMedCrossRef
56.
Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336–42.PubMedCrossRef
57.
Naraba H, Iwai N. Assessment of the microRNA system in salt-sensitive hypertension. Hypertens Res. 2005;28(10):819–26.PubMedCrossRef
58.
Liu Y, Taylor NE, Lu L, et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension. 2010;55(4):974–82.PubMedCrossRef
59.
• Albinsson S, Skoura A, Yu J, et al.: Smooth muscle miRNAs are critical for post-natal regulation of blood pressure and vascular function. PLoS One 2011, 6(4):e18869. This study demonstrates that in addition to embryonic development, miRNAs are also important in maintaining vascular smooth muscle cells and BP homeostasis in adult organisms.
60.
Sequeira-Lopez ML, Weatherford ET, Borges GR, et al. The microRNA-processing enzyme dicer maintains juxtaglomerular cells. J Am Soc Nephrol. 2010;21(3):460–7.PubMedCrossRef
61.
Harvey SJ, Jarad G, Cunningham J, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol. 2008;19(11):2150–8.PubMedCrossRef
62.
Ho J, Ng KH, Rosen S, et al. Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol. 2008;19(11):2069–75.PubMedCrossRef
63.
Shi S, Yu L, Chiu C, et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol. 2008;19(11):2159–69.PubMedCrossRef
64.
Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23(18):2166–78.PubMedCrossRef
65.
Sober S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun. 2010;391(1):727–32.PubMedCrossRef
66.
Ceolotto G, Papparella I, Bortoluzzi A, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24(2):241–6.PubMedCrossRef
67.
•• Sethupathy P, Borel C, Gagnebin M, et al.: Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007, 81(2):405–413. This is the first report of a polymorphism in an miRNA binding site that affects blood pressure.
68.
Elton TS, Sansom SE, Martin MM: Cardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection? Int J Hypertens 2010, published online 2010 Aug 4. doi:10.​4061/​2010/​281692.
69.
Wang L, Rao F, Zhang K, et al. Neuropeptide Y(1) Receptor NPY1R discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo. J Am Coll Cardiol. 2009;54(10):944–54.PubMedCrossRef
70.
Marmorstein R, Trievel RC. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta. 2009;1789(1):58–68.PubMed
71.
Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407–12.PubMedCrossRef
72.
73.
Tamura H, Schild L, Enomoto N, et al. Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene. J Clin Invest. 1996;97(7):1780–4.PubMedCrossRef
74.
Bonny O, Knoers N, Monnens L, Rossier BC. A novel mutation of the epithelial Na + channel causes type 1 pseudohypoaldosteronism. Pediatr Nephrol. 2002;17(10):804–8.PubMedCrossRef
75.
Zhang D, Yu ZY, Cruz P, et al. Epigenetics and the control of epithelial sodium channel expression in collecting duct. Kidney Int. 2009;75(3):260–7.PubMedCrossRef
76.
Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107–12.PubMedCrossRef
77.
• Mu S, Shimosawa T, Ogura S, et al.: Epigenetic modulation of the renal beta-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 2011, 17(5):573–580. This study implicates the epigenetic modulation of WNK4 transcription in the development of salt-sensitive hypertension.
78.
Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science. 1975;187(4173):226–32.PubMedCrossRef
79.
Riggs AD. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet. 1975;14(1):9–25.PubMedCrossRef
80.
81.
Frey FJ. Methylation of CpG islands: potential relevance for hypertension and kidney diseases. Nephrol Dial Transplant. 2005;20(5):868–9.PubMedCrossRef
82.
Muhonen P, Holthofer H. Epigenetic and microRNA-mediated regulation in diabetes. Nephrol Dial Transplant. 2009;24(4):1088–96.PubMedCrossRef
83.
Wilson AG. Epigenetic regulation of gene expression in the inflammatory response and relevance to common diseases. J Periodontol. 2008;79(8 Suppl):1514–9.PubMedCrossRef
84.
Wang X, Zhu H, Snieder H, et al. Obesity related methylation changes in DNA of peripheral blood leukocytes. BMC Med. 2010;8:87.PubMedCrossRef
85.
Lund G, Andersson L, Lauria M, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004;279(28):29147–54.PubMedCrossRef
86.
Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82(3):696–711.PubMedCrossRef
87.
Michalkiewicz M, Michalkiewicz T, MacGillis K: Combined epigenomic and genomic approach to hypertension. The FASEB Journal 2008, 22 (Meeting Abstract Suppl):968.
88.
Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens. 1996;14(8):935–41.PubMedCrossRef
89.
Poulter NR, Chang CL, MacGregor AJ, et al. Association between birth weight and adult blood pressure in twins: historical cohort study. BMJ. 1999;319(7221):1330–3.PubMedCrossRef
90.
McNeill G, Tuya C, Smith WC. The role of genetic and environmental factors in the association between birthweight and blood pressure: evidence from meta-analysis of twin studies. Int J Epidemiol. 2004;33(5):995–1001.PubMedCrossRef
91.
Bergvall N, Iliadou A, Johansson S, et al. Genetic and shared environmental factors do not confound the association between birth weight and hypertension: a study among Swedish twins. Circulation. 2007;115(23):2931–8.PubMedCrossRef
92.
Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes. 2005;54(7):1899–906.PubMedCrossRef
93.
Bogdarina I, Welham S, King PJ, et al. Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007;100(4):520–6.PubMedCrossRef
94.
Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab. 1999;84(10):3745–9.PubMedCrossRef
95.
Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest. 2004;114(8):1146–57.PubMed
96.
Baserga M, Kaur R, Hale MA, et al. Fetal growth restriction alters transcription factor binding and epigenetic mechanisms of renal 11beta-hydroxysteroid dehydrogenase type 2 in a sex-specific manner. Am J Physiol Regul Integr Comp Physiol. 2010;299(1):R334–342.PubMedCrossRef
97.
Friso S, Pizzolo F, Choi SW, et al. Epigenetic control of 11 beta-hydroxysteroid dehydrogenase 2 gene promoter is related to human hypertension. Atherosclerosis. 2008;199(2):323–7.PubMedCrossRef
98.
Smolarek I, Wyszko E, Barciszewska AM, et al.: Global DNA methylation changes in blood of patients with essential hypertension. Med Sci Monit 2010, 16(3):CR149-155.
99.
Yuen RK, Penaherrera MS, von Dadelszen P, et al. DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsia. Eur J Hum Genet. 2010;18(9):1006–12.PubMedCrossRef
Metadata
Title
Beyond Genome-Wide Association Studies: New Strategies for Identifying Genetic Determinants of Hypertension
Authors
Xiaoling Wang
Bram P. Prins
Siim Sõber
Maris Laan
Harold Snieder
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 6/2011
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0230-y

Other articles of this Issue 6/2011

Current Hypertension Reports 6/2011 Go to the issue

Clinical Trial Report

Salivary Cortisol Predicts Cardiovascular Mortality

Mediators, Mechanisms, and Pathways in Tissue Injury (Heinrich Taegtmeyer and Steven Atlas, Section Editors)

Effects of Relaxin on Arterial Dilation, Remodeling, and Mechanical Properties

Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Blood Pressure Targets for Patients with Diabetes or Kidney Disease

Mediators, Mechanisms in Tissue Injury (Heinrich Taegtmeyer, Steven Atlas, Section Editors)

The Roles of Integrins in Mediating the Effects of Mechanical Force and Growth Factors on Blood Vessels in Hypertension

Special Situations in the Management of Hypertension (Theodore Kotchen, Section Editor)

Immune Mechanisms in Hypertension

Invited Commentary

Improvement of Sodium Status to Optimize the Efficacy of Renin-Angiotensin System Blockade
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits